’Relative’ chemotherapy sensitivity: The impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin’s lymphoma

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 885-891

  Chen, C I ^a   Roitman, D ^a   Tsang, R ^a   Stewart, A K ^a   Keating, A ^a   Crump, M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Chemosensitivity; Chemotherapy; Lymphoma; Salvage; Transplant

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PACLITAXEL; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036956142     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703772     Document Type: Article

References (38)

1. Conde E, Sierra J, Iriondo A et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish cooperative Group GEL/TAMO. Bone Marrow Transplant 1994; 14: 279-286.
2. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-941.
3. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1989; 316: 1493-1498.
4. Rapaport AP, Lifton R, Constine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883-890.
5. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
6. Prince HM, Imrie K, Crump M et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880-889.
7. Bezwoda WR, Bezwoda MA, Seymour L et al. NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma. Leuk Lymphoma 1993; 10: 329-333.
8. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-697.
9. Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-412.
10. Girouard C, Dufresne J, Imrie K et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8: 675-680.
11. Goss P, Shepherd F, Scott JG et al. DICE (dexamathasone, ifosphamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995; 18: 123-129.
12. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-1741.
13. Sparano JA, Wiernick PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-1079.
14. Stamatoullas A, Fruchart C, Bastit D et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer 1996; 77: 2302-2307.
15. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
16. Wilson WH, Bryant G, Bates S et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-1582.
17. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
19. + cells. Blood 1997; 90: 214a.
20. International Non-Hodgkin's Lymphoma. Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-481.
22. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. JR Stat Soc A 1972; 135: 185-206.
23. Fleiss JL. Statistical Methods for Rates and Proportions. 1973, Wiley: New York.
24. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
25. McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunorubicin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
26. Younes A, Ayoub J-P, Hagemeister FB et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 1996; 14: 543-548.
27. Press OW, LeBlanc M, O'Rourke TJ et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology group Trial 9246. J Clin Oncol 1998; 16: 574-578.
28. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
29. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
30. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Centre experience. Hematol Oncol Clin N Amer 1997; 11: 937-947.
31. Blay J-Y, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998; 92: 3562-3568.
32. Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-791.
33. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
34. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264-3269.
35. Phillips GL, Fay JW, Herzig RH et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75: 831-838.
36. Vose JM, Peterson C, Bierman PJ et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 1990; 76: 424-431.
37. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
38. Goldstone AH, Singer CRJ, Gribben JG et al. Experience of autologous bone marrow transplantation in the first 100 lymphomas. Bone Marrow Transplant 1988; 3: 33-36.